Company Details
|
|
Address
|
Fetcham Park House, Lower Road, Leatherhead, KT22 9HD
|
|
Telephone
|
01372 371 171
|
|
Fax
|
|
Executives
|
|
Chairman
|
Graeme Hart (1.60% holding)
|
|
Chief Executive
|
Robert Mansfield (0.40% holding)
|
|
Finance Director
|
Graham Yeatman (0.40% holding)
|
|
Chief Scientific Officer
|
Michael Snape (10.90% holding)
|
Main Shareholders
|
|
|
Michael Hudson: 12.5%
Schroder Investment Management: 10.6%
Cazenove Capital Management: 10%
Insight Investments Management (Global): 10%
|
Advisers
|
|
Nominated Adviser
|
Investec Investment Banking
|
|
Nominated Broker
|
Investec Investment Banking
|
|
Solicitors
|
McGrigors
|
|
Auditors
|
Deloitte
|
|
Registrar
|
Equiniti
|
|
Commentary
|
|
Pharmaceutical group focused on the development of medicines for the treatment of neuro-developmental disorders
|
Company Data |
| Code |
NPH |
| Sedol |
GB00B1NPJJ |
| Shares In Issue |
31.537 m |
| Indices
|
|
| Entry on AIM |
06/03/2007 |
| Interim Results |
Feb |
| Final Results |
Sep |
| Year End |
Jun |
| Accounts Due |
Dec |
| Int div payment |
n/a |
| Fin div payment |
n/a |
| Int net div per share |
nil |
| Fin net div per share |
nil |
| Probable CGT relief |
Yes |
| |
|
|
